It is estimated that more than one million people worldwide suffering from ESRD are treated with some form of dialysis therapy, 10 to 15 percent of whom rely on a flexible daily PD regimen. The study, conducted by leading researchers in Mexico under the auspices of the Mexican health-care authorities , and supported by Baxter Healthcare Corporation and its Mexico affiliate, appears in the May issue (Volume 13, Issue 5) of the peer-reviewed publication, Journal of the American Society of Nephrology (JASN).
This is a pivotal study for the nephrology community worldwidefor both doctors and patients, said Salim Mujais, M.D., vice president of Global Medical Affairs for Baxters Renal business, and ADEMEX (Adequacy of Peritoneal Dialysis in Mexico) study author. The findings challenge existing treatment recommendations for PD, which may allow for greater flexibility in prescribing the therapy and potentially enable more patients to benefit from it.
The ADEMEX study is a multi-center, prospective, randomized, controlled trial of 965 continuous ambulatory PD patients in Mexico who were followed for a minimum of two years. The trial was designed to examine the effect of increasing PD small solute clearances a common measure of toxin removal and kidney function on mortality outcomes in patients with ESRD.
Until now, many kidney specialists prescribing PD have believed that increasing small solute clearances would result in better survival. However, ADEMEX researchers
Contact: Stephanie Lazor
Manning Selvage & Lee